Thus, among 4656 cases of LGMD [24] who underwent next-generation sequencing (NGS) tests, genetic identification was possible in 27% of cases, 17% of which were LGMD2A, 17% LGMD2B and 3% sarcoglycanopathies, LGMD2C-D-E-F. This evidence concerns the gene DYSF and limb-girdle muscular dystrophy.